GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (XCNQ:ACOG) » Definitions » FCF Margin %

Alpha Cognition (XCNQ:ACOG) FCF Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Alpha Cognition's Free Cash Flow for the three months ended in Mar. 2024 was C$-3.32 Mil. Alpha Cognition's Revenue for the three months ended in Mar. 2024 was C$0.00 Mil. Therefore, Alpha Cognition's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Alpha Cognition's current FCF Yield % is -10.38%.

The historical rank and industry rank for Alpha Cognition's FCF Margin % or its related term are showing as below:


XCNQ:ACOG's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -143.92
* Ranked among companies with meaningful FCF Margin % only.


Alpha Cognition FCF Margin % Historical Data

The historical data trend for Alpha Cognition's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition FCF Margin % Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Margin %
- - - -

Alpha Cognition Quarterly Data
Jan20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alpha Cognition's FCF Margin %

For the Biotechnology subindustry, Alpha Cognition's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpha Cognition's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's FCF Margin % falls into.



Alpha Cognition FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Alpha Cognition's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-11.711/0
= %

Alpha Cognition's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-3.323/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpha Cognition FCF Margin % Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Cognition (XCNQ:ACOG) Business Description

Traded in Other Exchanges
Address
301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2
Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.

Alpha Cognition (XCNQ:ACOG) Headlines

No Headlines